Procalcitonin-Guided Antibiotic Treatment in Lower Respiratory Tract Infections
PDF
Cite
Share
Request
Original Investigation
P: 72-78
August 2018

Procalcitonin-Guided Antibiotic Treatment in Lower Respiratory Tract Infections

J Acad Res Med 2018;8(2):72-78
1. Department of Pulmonary Medicine, İstanbul Yeni Yüzyıl University, School of Medicine, İstanbul, Turkey
2. Department of Pulmonary Medicine, Marmara University, School of Medicine, İstanbul, Turkey
No information available.
No information available
Received Date: 23.08.2017
Accepted Date: 05.12.2017
PDF
Cite
Share
Request

ABSTRACT

Objective:

Procalcitonin (PCT), C-reactive protein (CRP), and leukocyte count are important host response biomarkers to determine the presence of infection. The aim of the present study was to evaluate the usefulness of PCT with other markers in lower respiratory tract infections.

Methods:

A total of 78 patients with community-acquired pneumonia (CAP), chronic obstructive pulmonary disease (COPD) exacerbations, and healthy controls were evaluated. Baseline serum levels of PCT and CRP and leukocyte counts were assessed and repeated on day 7 of antibiotic treatment.

Results:

Procalcitonin levels and absolute neutrophil counts (ANCs) were higher in the CAP and COPD groups than in the control group. In the CAP and COPD exacerbation groups, the leukocyte count, ANC, and CRP and PCT levels decreased on day 7 of the treatment (p<0.001). In the CAP group, the baseline PCT levels were correlated with leukocyte counts (r=0.495, p<0.005), ANCs (r=0.426, p<0.019), and CRP levels (r=0.515, p<0.004). In receiver operating characteristic curve analysis, PCT threshold >0.12 ng/mL had a sensitivity of 70.4% and specificity of 68.7%, and CRP threshold >22.9 mg/L had a sensitivity of 85.2% and specificity of 75.0%.

Conclusion:

Procalcitonin is a useful marker to determine the initiation of antibiotic therapy and can also be used to cease the treatmen

Keywords: Procalcitonin, C-reactive protein, lower respiratory tract infection

References

2024 ©️ Galenos Publishing House